Patients and methods

Case report
This male patient was born at 36 weeks gestation with a birth weight of 2600 g. A cardiac murmur was pointed out at the age of 2 months. Echocardiography revealed mild hypertrophy of the left ventricle and interventricular septum with normal ejection fraction. At the age of 1 year, the patient underwent cardiac catheterization for a biopsy of the cardiac muscle, and abnormal-shaped mitochondria with dense bodies were revealed on electron microscopy. Serum lactate and pyruvate were mildly elevated, and serum carnitine was within normal range. At the age of 2 years, the patient's body height was 82 cm (Ϫ2 SD). He also showed cyclic neutropenia with an absolute neutrophil count as low as zero. During periods of neutropenia, his fever sometimes rose and he sometimes developed diarrhea. Urinary organic acids showed increased excretion of 3-methylgultaconic acid, 3-methylglutaric acid, and 3-hydroxyisovaleric acid. The activity of 3-methylglutaconyl CoA hydratase of cultured fibroblasts was within normal range (subject No. 1 in Gibson et al. 1991) . He was diagnosed as 3-methylglutaconic aciduria, type 2 (BTHS). At the last examination (17 years old), his body height was within normal range (165.7 cm). Despite exercise intolerance with palpitation, echocardiography showed normal ejection fraction without ventricular dilatation or hypertrophy. In association with his cyclic neutropenia, he also sometimes suffered from stomatitis or perianal abscesses.
Introduction
Barth syndrome (BTHS, MIM 302060) is an X-linked disorder associated with cardiac and skeletal myopathy, short stature, neutropenia, and abnormal mitochondria (Barth et al. 1983) . Because this syndrome includes increased urinary excretion of 3-methylglutaconic acid with normal activity of 3-methylglutaconyl coenzyme A (CoA) hydratase, some investigators also use the term "3-methylglutaconic aciduria, type 2" (Gibson et al. 1991) . Bione et al. (1996) implicated the TAZ (G4.5) gene at Xq28 as the gene responsible for BTHS. The gene products, His parents gave their informed consent for a genetic analysis. This study was approved by the Ethical Committee of the Tohoku University School of Medicine.
Direct sequencing of the TAZ (G4.5) gene Genomic DNA was extracted from leukocytes with the aid of a Sepa Gene Kit (Sanko Jun-yaku, Tokyo, Japan). Polymerase chain reaction (PCR) was used to amplify all 11 exons including the flanking introns. The sequences of primers for exon 3 were BTHS-KS3 (5Ј-CGAGGTCG ACGGTATCGGCTGTCCCTCATTCCCTG-3Ј) and BTHS-Rev3 (5Ј-CAGGAAACAGCTATGACATGCCC TGCCTGGACTG-3Ј). BTHS-KS3 and BTHS-Rev3 had the KS primer sequence (underlined) and M13 reverse sequence (double-lined) at the 5Ј ends of the primers, respectively, to facilitate the cycle sequencing reaction. Primer sequences for other exons are available from the authors on request. PCR products were separated on a 3% agarose gel and purified with a QIAquick Gel Extraction Kit (Promega, Madison, WI, USA). Cycle sequencing was performed using a Thermo Sequenase cycle sequencing kit and an A.L.F. red DNA sequencer (Amersham Pharmacia Biotech, Uppsala, Sweden).
PCR-restriction fragment length polymorphism for the R94S mutation PCR amplification was performed for exon 3 as described earlier. PCR products were digested with SfaNI (New England Biolabs, Beverly, MA, USA). Fragments were separated on a 3% agarose gel and visualized by ethidium bromide staining.
Results and discussion
In this patient, we found a C-to-A substitution within exon 3 in a hemizygous pattern, resulting in the replacement of arginine with serine (R94S) (Fig. 1A) . This R94S mutation abolishes an SfaNI site. PCR products digested with SfaNI showed that the patient was hemizygous and his mother was heterozygous for the R94S mutation (Fig. 1B) . The patient's father could not be studied.
Screening for the R94S mutation was performed in DNA samples from 55 healthy volunteers (male: 45, female: 10). All 65 alleles showed wild type (data not shown). The arginine at 94 is conserved in Caenorhabdities elegans and Saccharomyces cerevisiae homologues (D'Adamo et al. 1997) , and another patient with a missense mutation at the Fig. 1A,B. A Direct sequencing of exon 3 from genomic DNA. The patient showed a C-to-A substitution in a hemizygous pattern. B Detection of the R94S mutation by polymerase chain reaction (PCR)-restriction fragment length polymorphism. PCR products digested with SfaNI showed that the patient was hemizygous for the R94S mutation. The mother of the patient was heterozygous same position (R94C) has been previously reported (Johnston et al. 1997) . These data suggest that R94S is not a common polymorphism, but a disease-causing mutation.
Most patients with BTHS die from cardiac failure or sepsis within 1 year. The present patient had mild cardiac symptoms with normal ejection fraction and contracted no severe infections. Although his body height was Ϫ2 SD at the age of 2 years, he grew to normal height by the age of 17 years. Kelley et al. (1991) reported another affected adult (33 years old) with normal adult height, exercise intolerance, and no history of severe infection. Because there is no correlation between the genotype and phenotype of BTHS (Johnston et al. 1997) , some additional factors may be associated with the mild clinical futures of these two patients.
Almost all reported BTHS patients have been from Europe, North America, and Australia. To our knowledge, only two other cases have been reported in Asian populations: one Japanese (Sakamoto et al. 2001; Katsushima et al. 2002) and one Vietnamese (Ichida et al. 2001 ). However, Cantlay et al. (1999) have questioned whether BTHS is underdiagnosed. We agree that pediatricians and pediatric cardiologists should consider performing metabolic investigations and/or genetic tests for patients with infantile cardiomyopathy.
